Simone Biagini
Overview
Explore the profile of Simone Biagini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merli P, Algeri M, Galaverna F, Bertaina V, Lucarelli B, Boccieri E, et al.
Blood
. 2023 Sep;
143(3):279-289.
PMID: 37738655
TCRαβ/CD19 cell depletion is a promising graft manipulation technique frequently used in the context of human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (HSCT). We previously reported the results of...
2.
Merli P, Pagliara D, Mina T, Bertaina V, Li Pira G, Lazzaro S, et al.
Haematologica
. 2022 Aug;
107(12):2966-2971.
PMID: 36005558
No abstract available.
3.
Merli P, Algeri M, Galaverna F, Milano G, Bertaina V, Biagini S, et al.
Front Immunol
. 2020 Jun;
11:699.
PMID: 32477328
TcRαβ/CD19-cell depleted HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) represents a promising new platform for children affected by acute leukemia in need of an allograft and lacking a matched donor, disease...
4.
Li Pira G, Di Cecca S, Biagini S, Girolami E, Cicchetti E, Bertaina V, et al.
Front Immunol
. 2017 Apr;
8:332.
PMID: 28386262
Hematopoietic stem cell transplantation is standard therapy for numerous hematological diseases. The use of haploidentical donors, sharing half of the HLA alleles with the recipient, has facilitated the use of...
5.
Conforti A, Starc N, Biagini S, Tomao L, Pitisci A, Algeri M, et al.
Oncotarget
. 2016 Oct;
7(47):77416-77429.
PMID: 27764806
The risk of malignant transformation of ex-vivo expanded human mesenchymal stromal cells (huMSCs) has been debated in the last years; however, the biosafety of these cells after exposure to supramaximal...
6.
Li Pira G, Malaspina D, Girolami E, Biagini S, Cicchetti E, Conflitti G, et al.
Biol Blood Marrow Transplant
. 2016 Aug;
22(11):2056-2064.
PMID: 27519279
HLA-haploidentical family donors represent a valuable option for children requiring allogeneic hematopoietic stem cell transplantation (HSCT). Because graft-versus-host diseases (GVHD) is a major complication of HLA-haploidentical HSCT because of alloreactive...
7.
Li Pira G, Biagini S, Cicchetti E, Merli P, Brescia L, Milano G, et al.
Transfus Apher Sci
. 2016 May;
54(3):356-63.
PMID: 27209628
Hematopoietic Stem Cells Transplantation (HSCT) is an effective treatment for hematological and non-hematological diseases. The main challenge in autologous HSCT is purging of malignant cells to prevent relapse. In allogeneic...
8.
Mantelli M, Avanzini M, Rosti V, Ingo D, Conforti A, Novara F, et al.
Br J Haematol
. 2015 May;
170(6):826-36.
PMID: 26010568
Fanconi anaemia (FA) is an inherited disorder characterized by pancytopenia, congenital malformations and a predisposition to develop malignancies. Alterations in the haematopoietic microenvironment of FA patients have been reported, but...
9.
Conforti A, Taranta A, Biagini S, Starc N, Pitisci A, Bellomo F, et al.
J Transl Med
. 2015 May;
13:143.
PMID: 25947233
Background: Cystinosis is a rare autosomal recessive disease caused by mutations of the CTNS gene, which encodes for a lysosomal cystine/H(+) symporter. In mice, inactivation of the CTNS gene causes...
10.
Rosado M, Bernardo M, Scarsella M, Conforti A, Giorda E, Biagini S, et al.
Stem Cells Dev
. 2014 Jul;
24(1):93-103.
PMID: 25036865
Bone marrow (BM)-derived mesenchymal stromal cells (MSCs), endowed with immunosuppressive and anti-inflammatory properties, represent a promising tool in immunoregulatory and regenerative cell therapy. Clarifying the interactions between MSCs and B-lymphocytes...